Tybriva 140mg Capsule

Tybriva 140mg Capsule consists of the active ingredient Ibrutinib. It is indicated to treat blood cancers such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (CLL), Waldenstrom’s macroglobulinemia, and Marginal zone lymphoma (MZL). These are cancers of the white blood cells called lymphocytes that are part of the immune system. They differ from each other by the location where cancer occurs, type of lymphocytes affected, and certain other factors

Tybriva 140mg Capsule is also used to treat chronic graft versus host disease (cGvHD) after the failure of systemic therapy. During allogeneic stem cell transplantation, the patient receives stem cells from the donor. GvHD occurs when donor cells attack the patient’s cells as foreign. Before taking Tybriva 140mg Capsule, you need to talk with your physician if you have bleeding problems, infection, liver problems, heart problems, or intolerance to some sugars. This medication is not recommended for adolescents and children.

It is vital to let the physician know if you have recently had or are about to have any surgical procedure. Your physician may stop Tybriva 140mg Capsule for any planned surgical or medical procedure. Use effective birth control during the treatment and for at least one month after the final dose. Avoid having grapefruit or oranges in any form during this treatment; they may raise the amount of drug in the blood. Drink plenty of fluid to prevent dehydration. Inform your physician if you have diarrhea that does not go away.